文献速递MDS 与骨髓增殖性肿瘤白血病造血干细胞移植与细胞治疗

加速期与急变期骨髓增殖性肿瘤的进展:我们是否在取得进步?

Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?
PubMed 文献 · Br J Haematol · 2023-08-01

本文综述加速期和急变期骨髓增殖性肿瘤的发病机制、当前治疗手段及现实结局;不适合异基因造血细胞移植的急变期患者结局总体仍很差,估计生存率常不足6个月;目前尚无免疫、基因组或临床病理标志能准确预测转化风险与时机,并讨论了新型药物进入临床后的前景。

要点

  • 不适合异基因造血细胞移植的急变期患者结局总体仍很差,估计生存率常不足6个月。
  • 目前尚无免疫、基因组或临床病理标志能准确预测加速期或急变期转化的风险与时机。
  • 本文综述加速期与急变期疾病的发病机制、当前治疗手段、现实结局及新型药物前景。

核心结论

  • 尽管治疗已有许多进展,不适合异基因造血细胞移植的急变期骨髓增殖性肿瘤患者结局总体仍很差,估计生存率常报告为不足6个月。
  • 目前尚无特定的免疫、基因组或临床病理标志能准确预测转化的风险与时机。

研究设计与样本

  • 本文为综述,汇总当前对加速期和急变期骨髓增殖性肿瘤发病机制的认识,并讨论当前治疗手段、现实结局及新型药物进入临床后的前景。

主要发现

  • 不适合异基因造血细胞移植的急变期患者结局总体仍很差,估计生存率常报告为不足6个月。
  • 目前尚无特定的免疫、基因组或临床病理标志能准确预测转化的风险与时机,转化常给患者和临床医生带来高度焦虑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Management approaches for accelerated and blast phase myeloproliferative neoplasms remain challenging for clinicians and patients alike. Despite many therapeutic advances, outcomes for those patients who are not allogeneic haematopoietic cell transplant eligible remain, in general, very poor. Estimated survival rates for such blast phase patients is frequently reported as less than 6 months. No specific immunological, genomic or clinicopathological signature currently exists that accurately predicts the risk and timing of transformation, which frequently induces a high degree of anxiety among patients and clinicians alike. Within this review article, we provide an up-to-date summary of current understanding of the underlying pathogenesis of accelerated and blast phase disease and discuss current therapeutic approaches and realistic outcomes. Finally, we discuss how the horizon may look with the introduction of more novel agents into the clinical arena.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mahdi D, Spiers J, Rampotas A, et al. Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress? Br J Haematol. 2023. PMID: 37527977. doi:10.1111/bjh.19010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。